Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States is how to ensure that prices are affordable, represent a sufficient reward to industry for the innovation it provides, and reflect the benefit that patients get from the medications they take.
Higher prices should mean better health, right?
